References
- 1. Amin MB, Crotty TB, Tickoo SK, Farrow GM. Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases // Am J Surg Pathol, 1997; 21:1 - 12
- 2. Choudhary S, Rajesh A, Mayer NJ, Mulcahy K, Haroon A. Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms // Clin Radiol, 2009; 64:517 - 522
- 3. Esheba GES, Esheba NES. Angiomyolipoma of the kidney: Clinicopathological and immunohistochemical study // J Egypt Natl Canc Inst, 2013; 25:125 - 134
- 4. Halpenny D, Snow A, McNeill G, Torreggiani WC. The radiological diagnosis and treatment of renal angiomyolipoma-current status // Clin Radiol, 2010; 65(2):99 - 108
- 5. Hanley J, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve // Diagnostic Radiol, 1982; 143(4):29 - 36
- 6. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: A need to reassess treatment effect // J Natl Cancer Inst, 2006; 98:1331 - 1334
- 7. Kawaguchi S, Fernandes K, Finelli A, Robinette M, Fleshner N, Jewett MS. Most renal oncocytomas appear to grow: Observations of tumor kinetics with active surveillance. J Urol, 2011; 186:1218 -1222
- 8. Kurup AN, Thompson RH, Leibovich BC, et al. Renal oncocytoma growth rates before intervention. BJU Int, 2012;110:1444 - 1448
- 9. Lindkvist Pedersen C, Winck-Flyvholm L, Dahl C, Azawi NH. High rate of benign histology in radiologically suspect renal lesions // Dan Med J, 2014; 61(10):A 4932
- 10. Ljungberg B, Bensalah K, Canfield S, et al. EAU Guidelines on Renal Cell Carcinoma: 2014 Update // Eur Urol, 2015; 67(5):913 - 924
- 11. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults // Eur Urol, 2006; 49(5):798 - 805
- 12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation // Nature, 2008; 454(7203):436 - 444
- 13. Mao Y, Poschke I, Kiessling R. Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells // J Intern Med, 2014; 276(2):154 - 170
- 14. Mues AC, Palacios JM, Haramis G, Casazza C, Badani K, Gupta M, et al. Contemporary experience in the management of angiomyolipoma. J Endourol // 2010; 24:1883 - 1886
- 15. Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer // Am J Clin Oncol, 2000; 23(3):263 - 266
- 16. Roxburgh CSD, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer // Future Oncol, 2010; 6:149 - 163
- 17. Santoni M, Massari F, Amantini C, et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma // Cancer Immunol Immunother, 2013; 62(12):1757 - 1768
- 18. spkc.gov.lv [Internet]. Riga: Statistical yearbook of health care in Latvia 2013. Public health and morbidity; Register of patients with particular disease, patients with cancer; [updated 2014 Jul 07; citated 2015 Apr 05]. Available from: http://www.spkc.gov.lv/veselibas-aprupes-statistika/
- 19. spkc.gov.lv [Internet]. Riga: Statistical yearbook of health care in Latvia 2013. Mortality; [updated 2014 Jul 07; citated 2015 Apr 05]. Available from: http://www.spkc.gov.lv/veselibas-aprupes-statistika/
- 20. Wu Y, Fu X, Zhu X, Zou C, Han Y, Xu M, et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: A systematic review and meta-analysis // J Cancer Res Clin Oncol, 2011; 137:887 - 889